Curis Inc (CRIS)vsVertex Pharmaceuticals Inc (VRTX)
CRIS
Curis Inc
$0.83
-5.62%
HEALTHCARE · Cap: $2.01M
VRTX
Vertex Pharmaceuticals Inc
$526.19
+0.73%
HEALTHCARE · Cap: $130.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 291676% more annual revenue ($12.59B vs $4.31M). VRTX leads profitability with a 35.0% profit margin vs 0.0%. CRIS trades at a lower P/E of 0.2x. VRTX earns a higher WallStSmart Score of 64/100 (C+).
CRIS
Avoid34
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+80.8%
Fair Value
$5.53
Current Price
$0.83
$4.70 discount
Margin of Safety
+45.6%
Fair Value
$960.21
Current Price
$526.19
$434.02 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -166.6% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CRIS
The strongest argument for CRIS centers on P/E Ratio, Price/Book, Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : CRIS
The primary concerns for CRIS are EPS Growth, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CRIS profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
CRIS carries more volatility with a beta of 3.00 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 34/100), backed by strong 35.0% margins and 12.5% revenue growth. CRIS offers better value entry with a 80.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Curis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?